3rd Quarter - Report

MERCK & CO, INC. for MERCK & CO INC

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
—
Expenses
$1,490,000
Expense method
A: Lobbying Disclosure Act definitions

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
3rd Quarter - Report (this page) Oct 19, 2015 $1,490,000 Replaced
3rd Quarter - Amendment Feb 1, 2016 $1,380,000 Yes

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Trade (domestic/foreign) TRD

Trans-Pacific Partnership, data exclusivity for biologics

LobbyistCovered position, as disclosed
ROBERT FILIPPONE —
ELI JOSEPH —
KATIE OPPENHEIM —
ERIN POLAK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Taxation/Internal Revenue Code TAX

Comprehensive tax reform (no specific bill), international tax proposals (no specific bill), orphan drug legislation (S.1128), base erosion (no specific bill), territorial tax system (no specific bill),

LobbyistCovered position, as disclosed
ROBERT FILIPPONE —
ELI JOSEPH —
KATIE OPPENHEIM —
ERIN POLAK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1128 (114th)

Copyright/Patent/Trademark CPT

Intellectual property (general education), patent reform (H.R. 9, the Innovation Act; S.632, the STRONG Patents Act)

LobbyistCovered position, as disclosed
ROBERT FILIPPONE —
ELI JOSEPH —
JENELLE KRISHNAMOORTHY —
KATIE OPPENHEIM —
ERIN POLAK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 9 (114th), S. 632 (114th)

Health Issues HCR

340B (no specific bill), Oncology education (no specific bill), adult vaccine policies (no specific bill), adolescent vaccine policies (no specific bill), DISARM (H.R. 4187), biosimilars (no specific bill), 21st Century Cures (H.R.6), FDA Regulatory Issues (no specific bill), general pharmaceutical industry issues, Innovation for Healthy Americans (no bill number)

LobbyistCovered position, as disclosed
ERIN DARLING —
ROBERT FILIPPONE —
ELI JOSEPH —
JENELLE KRISHNAMOORTHY —
KATIE OPPENHEIM —
ERIN POLAK —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 4187 (114th), H.R. 6 (114th)

Medicare/Medicaid MMM

Medicare Part D (general education, no specific bill), changes to low-income subsidy structure in Medicare Part D (general education, no specific bill), Medicare Part B (general education, no specific bill)

LobbyistCovered position, as disclosed
ERIN DARLING —
ROBERT FILIPPONE —
ELI JOSEPH —
JENELLE KRISHNAMOORTHY —
KATIE OPPENHEIM —
ERIN POLAK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Animals ANI

Fairness to Pet Owners (S.1200), general animal health issues

LobbyistCovered position, as disclosed
ELI JOSEPH —
KATIE OPPENHEIM —
ERIN POLAK —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: S. 1200 (114th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.